Literature DB >> 15181244

APOE genotype effects on Alzheimer's disease onset and epidemiology.

J Wesson Ashford1.   

Abstract

The risk of developing Alzheimer's disease (AD) is tied most closely to age and appears to follow Gompertzian kinetics. However, specific genetic factors are also linked closely to AD, and the apolipoprotein E (APOE) genotype accounts for as much of 50% of the attributable risk for AD in many populations. This paper reviews the onset, diagnosis, and epidemiology of AD, specifically with regard to the APOE genotype and the interaction of the genotype with age. Copyright 2004 Humana Press Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15181244     DOI: 10.1385/JMN:23:3:157

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  46 in total

Review 1.  Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles.

Authors:  M M Mesulam
Journal:  Neuron       Date:  1999-11       Impact factor: 17.173

2.  Apolipoprotein E genotypes and the incidence of Alzheimer's disease among persons aged 75 years and older: variation by use of antihypertensive medication?

Authors:  Z Guo; L Fratiglioni; M Viitanen; L Lannfelt; H Basun; J Fastbom; B Winblad
Journal:  Am J Epidemiol       Date:  2001-02-01       Impact factor: 4.897

3.  The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

Authors:  G Blessed; B E Tomlinson; M Roth
Journal:  Br J Psychiatry       Date:  1968-07       Impact factor: 9.319

4.  Growth processes in teeth distinguish modern humans from Homo erectus and earlier hominins.

Authors:  C Dean; M G Leakey; D Reid; F Schrenk; G T Schwartz; C Stringer; A Walker
Journal:  Nature       Date:  2001-12-06       Impact factor: 49.962

5.  Temporal quantification of Alzheimer's disease severity: 'time index' model.

Authors:  J W Ashford; M Shan; S Butler; A Rajasekar; F A Schmitt
Journal:  Dementia       Date:  1995 Sep-Oct

6.  Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons.

Authors:  D A Evans; L A Beckett; T S Field; L Feng; M S Albert; D A Bennett; B Tycko; R Mayeux
Journal:  JAMA       Date:  1997-03-12       Impact factor: 56.272

7.  Longevity and the epsilon2 allele of apolipoprotein E: the Finnish Centenarians Study.

Authors:  G B Frisoni; J Louhija; C Geroldi; M Trabucchi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2001-02       Impact factor: 6.053

8.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

9.  Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions.

Authors:  T G Ohm; H Scharnagl; W März; J Bohl
Journal:  Acta Neuropathol       Date:  1999-09       Impact factor: 17.088

10.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

View more
  85 in total

1.  Repositioning leptin as a therapy for Alzheimer's disease.

Authors:  Jane M Johnston; Steven J Greco; Ashkan Hamzelou; J Wesson Ashford; Nikolaos Tezapsidis
Journal:  Therapy       Date:  2011-09

2.  Alzheimer's disease: new therapies and the role of biomarkers.

Authors:  Kellie Dudash
Journal:  Biotechnol Healthc       Date:  2011

Review 3.  Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics.

Authors:  Kelly M Bakulski; Laura S Rozek; Dana C Dolinoy; Henry L Paulson; Howard Hu
Journal:  Curr Alzheimer Res       Date:  2012-06       Impact factor: 3.498

4.  Apolipoprotein E genotype is associated with temporal and hippocampal atrophy rates in healthy elderly adults: a tensor-based morphometry study.

Authors:  Po H Lu; Paul M Thompson; Alex Leow; Grace J Lee; Agatha Lee; Igor Yanovsky; Neelroop Parikshak; Theresa Khoo; Stephanie Wu; Daniel Geschwind; George Bartzokis
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.

Authors:  John B Rose; Leslie Crews; Edward Rockenstein; Anthony Adame; Michael Mante; Louis B Hersh; Fred H Gage; Brian Spencer; Rewati Potkar; Robert A Marr; Eliezer Masliah
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

6.  Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease.

Authors:  Luke Whiley; Arundhuti Sen; James Heaton; Petroula Proitsi; Diego García-Gómez; Rufina Leung; Norman Smith; Madhav Thambisetty; Iwona Kloszewska; Patrizia Mecocci; Hilkka Soininen; Magda Tsolaki; Bruno Vellas; Simon Lovestone; Cristina Legido-Quigley
Journal:  Neurobiol Aging       Date:  2013-09-13       Impact factor: 4.673

7.  Genetic Polymorphisms Influence Cognition in Patients Undergoing Carotid Interventions.

Authors:  Elizabeth Hitchner; Doug Morrison; Phoebe Liao; Allyson Rosen; Wei Zhou
Journal:  Int J Angiol       Date:  2016-04-08

Review 8.  Antioxidant therapy in Alzheimer's disease: theory and practice.

Authors:  Gjumrakch Aliev; Mark E Obrenovich; V Prakash Reddy; Justin C Shenk; Paula I Moreira; Akihiko Nunomura; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Mini Rev Med Chem       Date:  2008-11       Impact factor: 3.862

Review 9.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

10.  Using genetics to enable studies on the prevention of Alzheimer's disease.

Authors:  D G Crenshaw; W K Gottschalk; M W Lutz; I Grossman; A M Saunders; J R Burke; K A Welsh-Bohmer; S K Brannan; D K Burns; A D Roses
Journal:  Clin Pharmacol Ther       Date:  2012-11-07       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.